Rituximab for rheumatoid arthrits treatment: A systematic review

Revista Brasileira de Reumatologia

Volumn 54, Issue 3, 2014, Pages 220-230

  de Lemos, Lívia Lovato Pires ^a   Costa, Juliana de Oliveira ^a   Machado, Marina Amaral de Ávila ^a   Almeida, Alessandra Maciel ^a   Barbosa, Mariana Michel ^b   Kakehasi, Adriana Maria ^a   de Araújoa, Vânia Eloísa ^a   Júnior, Augusto Afonso Guerra ^a   Acurcioa, Francisco de Assis ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Efficacy; Rheumatoid arthritis; Rituximab; Safety; Systematic review

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

DAS28; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; GENETIC HETEROGENEITY; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH SURVEY; HUMAN; OUTCOME ASSESSMENT; REVIEW; RHEUMATOID ARTHRITIS; SHORT FORM 36; SYSTEMATIC REVIEW; ARTHRITIS, RHEUMATOID; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; RITUXIMAB; TREATMENT OUTCOME;

EID: 84904673246     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbre.2013.08.003     Document Type: Short Survey

References (50)

1. McInnes IB and Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-2219.
2. Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ. Outcome after 40 years with rheumatoid arthritis: A prospective study of function, disease activity, and mortality. J Rheumatol. 2004;31; Suppl 69:3-8.
3. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hiek K. The links between joint damage and disability in rheumatoid arthritis. Rheumatology. 2000;39:122-132.
4. Alamanos Y, Voulgari PV, Drosos AA. Incidence and Prevalence of Rheumatoid Arthritis, Based on the 1987 American College of Rheumatology Criteria: A Systematic Review. Semin Arthritis Rheum. 2006;36:182-188.
5. Gonzalez A, Kremers HM, Crowson CS, Nicola PJ, Davis JM, Therneau TM, Roger VL, Gabriel SE. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56:3583-3587.
6. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstro DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing tnf blocking agents in treatment of rheumatoid arthritis. PLoS ONE. 2012;: e30275. doi:10.1371/journal.pone.0030275.
7. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of diseasemodifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Rheum. 2012;64:625-639.
8. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-975.
9. Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, Montoro M, Descalzo MA, Carmona L, on behalf of the BIOBADASER 2.0 Study Group Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0 Ann Rheum Dis. 2012;71:382-385.
10. Volkmann ER, Agrawal H, Maranian P and Furst DE. Rituximab for rheumatoid arthritis: A meta-analysis and systematic review. Clinical Medicine Insights: Therapeutics. 2010;749-760.
11. Hernández-Cruz B, García-Arias M, Ariza RA, Molab EM. Rituximab in rheumatoid arthritis: A systematic review of ef?cacy and safety. Reumatol Clin. 2011;7:314-322.
12. Lee YH, Bae S-C, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2011;31:1493-1499.
13. Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technology Assessment. 2011;15:1-278.
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO et al. Rheumatoid Arthritis Classification Criteria. Arthritis Rheum. 2010;62:2569-2581.
15. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updatet in mar. 2011]. The Cochrane Collaboration, 2011. Available from: www. cochrane-handbook.org.
16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Brit Med J. 2009;339:b2700.
17. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al. American-College-of-Rheumatology preliminary definition of improvement in rheumatoidarthritis. Arthritis Rheum. 1995;38:727-735.
18. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S93-99.
19. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey: I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
20. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short- Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-263.
21. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811-819.
22. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technology Assessment. 2005; 9:1-+. PubMed PMID: WOS:000229604400001.
23. Higgins JPT, Altman AD, Sterne JAC. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated in mar. 2011]. Disponível em: www.cochrane-handbook.org, 2012.
24. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1997;33:159-174.
25. Deeks JJ HJ, altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: HIGGINS JPT, GREEN S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated in mar. 2011]. Disponível em: www. cochrane-handbook.org; 2012.
26. Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Mcshane JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324
27. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W et al for the IMAGE Investigators. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2010;7:39-46.
28. Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Rheum. 2011;63:711-720.
29. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351-357.
30. Emery P, Deodhar A, Rigby WF, Isaacs JD, CombeB, Racewicz AJ et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebocontrolled trialin patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequater Esponders (SERENE)). Ann Rheum Dis. 2010;69:1629-1635.
31. Edwards JCW, Szczepański L, Szechiński J, Filipowicz-Sosnowska A, Emery P, Close DR et al. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthiritis. N Engl J Med. 2004;350:2578-2581.
32. Emery P, Sheeran T, Lehane PB, Saiedabadi N, Shaw TM. Efficacy and safety of rituximab at 2 years following a single treatment in patients with active rheumatoid arthritis. Arthritis Rheum. 2004;50:1344-50.
33. Keystone EC. B cells in rheumatoid arthritis: from hypothesis to the clinic. Rheumatology. 2005; 44(Suppl. 2):ii8-ii12.
34. Strand V, Balbir-Gurman A, Pavelka K, Emery P, Li N, Yin M et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology. 2006;45:1505-1513.
35. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechetman J, Szczepanski L, Kavanaugh A et al for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum. 2006;54:1390-1400.
36. Mease PJ, Revicki DA, Szczepanski J, Greenwald M, KIvitz A, Barile-Fabris L et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab-results of the dose-ranging assessment: international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial. J Rheumatol. 2008;35:20-30.
37. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC et al for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:2793-2806.
38. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J et al. Improvement in patient-reposted outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2008;59:785-93.
39. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC et al. Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. Ann Rheum Dis. 2009;68:216-221.
40. Cohen SB, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximabin combination with methotrexate. Ann Rheum Dis. 2010;59:1158-1161.
41. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010; 37:917-927.
42. Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Muller-Ladner U, Gaylis NB et al. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology. 2011;50:2223-2232.
43. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay J-L, Carreno L, Armstrong G et al. Shaw TM on behalf of the MIRROR Trial Investigators. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology. 2010;49:1683-1693.
44. Van Vollenhoven RF, Emery P, Bingham III CO, Keystone EC, Fleischmann R, Furst DE et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37:558-567.
45. Bingham C, Looney R, Deodhar A, Halsey N, Greenwald M, Codding C et al. Results from a controlled clinical trial (SIERRA) to evaluate primary and recall responses to immunizations in RA patients treated with rituximab [abstract]. Arthritis Rheum Suppl. 2008;58:S900.
46. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, Kyburz D, Dudler J, Gabay C, on the behalf of the doctors of the Swiss Clinical Management Programme for Rheumatoid Arthritis. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumor necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69;387-393.
47. Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I et al. Effectiveness of a third tumor necrosis factor- a-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. J Rheumatol. 2011;38:2355-2361.
48. Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007; 4:e184. doi:10.1371/journal. pmed.0040184.
49. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167. doi:10.1136/bmj.326.7400.1167.
50. Michaud K and Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2007;21:885-906.